Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia
International Journal of Tuberculosis and Lung Disease, Volume 16, No. 6, Year 2012
Notification
URL copied to clipboard!
Description
SETTING: Gondar Hospital, Gondar Health Centre, Metemma Hospital, Bahir Dar Hospital and Debre Markos Hospital in Northwest Ethiopia. OBJECTIVE: To assess the level of and risk factors for first- and second-line drug resistance among tuberculosis (TB) patients. DESIGN: Drug susceptibility testing (DST) against first-line drugs, including isoniazid (INH), rifampicin (RMP), streptomycin (SM), ethambutol (EMB) and pyrazinamide (PZA), was performed using the BacT/ALERT 3D system. DST against second-line drugs, including fluoroquinolones and aminoglycocides/cyclic peptides, was performed using GenoType MTBDRsl. RESULTS: Of 260 Mycobacterium tuberculosis isolates, 41 (15.8%) were resistant to at least one first-line drug, 13 (5.0%) were multidrug-resistant (MDR) and 9 (3.5%) were resistant to all first-line drugs. Any resistance to INH, RMP, SM, EMB and PZA was respectively 36 (13.8%), 15 (5.8%), 26 (10.0%), 19 (7.3%) and 12 (4.6%). Of 214 new and 46 previously treated cases, respectively 8 (3.7%) and 5 (10.9%) were MDR. All isolates were susceptible to all second-line drugs. CONCLUSION: A substantial number of new and previously treated cases harbour MDR-TB. We recommend DST at least for previously treated cases, patients who remain smear-positive at the end of the second month of treatment and patients in close contact with MDR-TB cases. Improved infection control measures need to be implemented in Ethiopia. © 2012 The Union.
Authors & Co-Authors
Tessema, Belay
Ethiopia, Gondar
University of Gondar
Germany, Leipzig
Universitätsklinikum Leipzig Und Medizinische Fakultät
Beer, Joerg
Germany, Leipzig
Universitätsklinikum Leipzig Und Medizinische Fakultät
Emmrich, Frank
Germany, Leipzig
Universitätsklinikum Leipzig Und Medizinische Fakultät
Germany, Leipzig
Fraunhofer Institute for Cell Therapy and Immunology Izi
Sack, Ulrich
Germany, Leipzig
Universitätsklinikum Leipzig Und Medizinische Fakultät
Germany, Leipzig
Fraunhofer Institute for Cell Therapy and Immunology Izi
Rodloff, Arne Christian
Germany, Leipzig
Universitätsklinikum Leipzig Und Medizinische Fakultät
Statistics
Citations: 63
Authors: 5
Affiliations: 3
Identifiers
Doi:
10.5588/ijtld.11.0522
ISSN:
10273719
Research Areas
Genetics And Genomics
Health System And Policy
Infectious Diseases
Study Locations
Ethiopia